Daniel Barrowdale
Overview
Explore the profile of Daniel Barrowdale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
5752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Mar;
30(5):630-631.
PMID: 35314806
No abstract available.
2.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Jan;
30(3):349-362.
PMID: 35027648
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance...
3.
Freeberg M, Fromont L, DAltri T, Romero A, Ciges J, Jene A, et al.
Nucleic Acids Res
. 2021 Nov;
50(D1):D980-D987.
PMID: 34791407
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research...
4.
Barnes D, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, et al.
J Natl Cancer Inst
. 2021 Jul;
114(1):109-122.
PMID: 34320204
Background: Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for...
5.
Lakeman I, van den Broek A, Vos J, Barnes D, Adlard J, Andrulis I, et al.
Genet Med
. 2021 Jun;
23(9):1726-1737.
PMID: 34113011
Purpose: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant...
6.
Coignard J, Lush M, Beesley J, OMara T, Dennis J, Tyrer J, et al.
Nat Commun
. 2021 May;
12(1):2986.
PMID: 33990587
A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-23162-4.
7.
Coignard J, Lush M, Beesley J, OMara T, Dennis J, Tyrer J, et al.
Nat Commun
. 2021 Feb;
12(1):1078.
PMID: 33597508
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers....
8.
Schrijver L, Antoniou A, Olsson H, Mooij T, Roos-Blom M, Azarang L, et al.
Am J Obstet Gynecol
. 2021 Jan;
225(1):51.e1-51.e17.
PMID: 33493488
Background: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in...
9.
Barnes D, Rookus M, McGuffog L, Leslie G, Mooij T, Dennis J, et al.
Genet Med
. 2020 Jul;
22(10):1653-1666.
PMID: 32665703
Purpose: We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers. Methods:...
10.
Silvestri V, Leslie G, Barnes D, Agnarsson B, Aittomaki K, Alducci E, et al.
JAMA Oncol
. 2020 Jul;
6(8):1218-1230.
PMID: 32614418
Importance: The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk...